These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 3825604)

  • 21. Low serum aluminum values in dialysis patients with increased bone aluminum levels.
    van Landeghem GF; D'Haese PC; Lamberts LV; Djukanovic L; Pejanovic S; Goodman WG; De Broe ME
    Clin Nephrol; 1998 Aug; 50(2):69-76. PubMed ID: 9725776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
    Nasri H; Baradaran A; Naderi AS
    Acta Med Austriaca; 2004 Aug; 31(3):67-72. PubMed ID: 15515479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of desferrioxamine on aluminum kinetics during hemodialysis.
    Stummvoll HK; Graf H; Meisinger V
    Miner Electrolyte Metab; 1984; 10(4):263-6. PubMed ID: 6749073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors influencing serum aluminum in CAPD patients.
    Montenegro J; Aguirre R; Saracho R; Moina I; Martínez I
    Clin Nephrol; 1998 Aug; 50(2):77-83. PubMed ID: 9725777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aluminum in chronic hemodialysis. Possible influence on osteomalacic bone disease.
    Quarello F; Giachino G; Bossi P; Gilli G; Corrao G; Scursatone E; Jeantet A; Bossi R; Coppo R; Piccoli G; Vercellone A
    Minerva Nefrol; 1980; 27(4):635-44. PubMed ID: 7254691
    [No Abstract]   [Full Text] [Related]  

  • 26. Aluminum kinetics of the REDY system: a study of the impact of deferoxamine therapy.
    Culpepper CP; Cummings R; Westervelt FB; Savory J; Wills MR
    Trans Am Soc Artif Intern Organs; 1983; 29():76-80. PubMed ID: 6673321
    [No Abstract]   [Full Text] [Related]  

  • 27. Epidemiology of aluminium toxicity in a 'low incidence' area.
    Winney RJ; Cowie JF; Cumming AD; Short AI; Smith GD; Robson JS
    Contrib Nephrol; 1984; 38():47-58. PubMed ID: 6713900
    [No Abstract]   [Full Text] [Related]  

  • 28. Continuous ambulatory EEG monitoring following desferrioxamine (DFO) i.v. infusion.
    Poignet JL; Monge MF; Ciancioni C; Mikol F; Naret C; Delons S; Man NK
    Trans Am Soc Artif Intern Organs; 1985; 31():546-51. PubMed ID: 3837504
    [No Abstract]   [Full Text] [Related]  

  • 29. Serum aluminum levels in dialysis dementia.
    McKinney TD; Basinger M; Dawson E; Jones MM
    Nephron; 1982; 32(1):53-6. PubMed ID: 7177277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intradialytic changes of serum magnesium and their relation to hypotensive episodes in hemodialysis patients on different dialysates.
    Elsharkawy MM; Youssef AM; Zayoon MY
    Hemodial Int; 2006 Oct; 10 Suppl 2():S16-23. PubMed ID: 17022745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Levels of serum glycosaminoglycans in renal failure.
    Mitsuhashi M; Mitsuhashi H; Yano S; Tsukada Y; Nojima Y; Naruse T
    Res Commun Mol Pathol Pharmacol; 1998 Feb; 99(2):225-32. PubMed ID: 9583096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
    Nasri H; Baradaran A
    J Ayub Med Coll Abbottabad; 2004; 16(2):3-8. PubMed ID: 15455608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes of metal concentrations in blood and peritoneal dialysate during long-term desferrioxamine B therapy.
    Romero RA; Salgado O; Elejalde LE; Rodríguez-Iturbe B; Tahán JE
    Transplant Proc; 1996 Dec; 28(6):3385-7. PubMed ID: 8962321
    [No Abstract]   [Full Text] [Related]  

  • 35. [Aluminum concentration in blood of hemodialysis patients and its clinical importance].
    Skarupskiene I; Kuzminskis V; Abdrachmanovas O; Ryselis S; Smalinskiene A; Naginiene R
    Medicina (Kaunas); 2003; 39 Suppl 1():104-8. PubMed ID: 12761430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of a desferrioxamine "microdose" to chelate aluminum in hemodialysis patients.
    Jorge C; Gil C; Possante M; Catarino MC; Cruz A; Andrade R; Teixeira R; Santos N; Ferreira A
    Clin Nephrol; 1999 Nov; 52(5):335-6. PubMed ID: 10585000
    [No Abstract]   [Full Text] [Related]  

  • 37. [Indications for desferrioxamine in patients with chronic renal insufficiency treated by dialysis].
    Simon P
    Nephrologie; 1986; 7(5):177-80. PubMed ID: 3822038
    [No Abstract]   [Full Text] [Related]  

  • 38. Acute and chronic influence of hemodialysis according to the membrane used on phagocytic function of neutrophils and monocytes and pro-inflammatory cytokines production in chronic renal failure patients.
    Muniz-Junqueira MI; Braga Lopes C; Magalhães CA; Schleicher CC; Veiga JP
    Life Sci; 2005 Nov; 77(25):3141-55. PubMed ID: 16005905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Kinetics of aluminum absorption and serum concentration in chronic renal insufficiency].
    Sárszegi Z; Jobst K; Nagy J
    Orv Hetil; 2000 Aug; 141(35):1915-7. PubMed ID: 11019592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trend evaluation of aluminium in uraemic patients on chronic hemodialysis.
    Di Iorio BR; Scarpino L; Bruno A; Confessore A; Gaudiano G; Altieri C; Smilari F; Papaleo D; Cosentino G; Terracciano V
    Nephron; 1995; 71(4):471-2. PubMed ID: 8587634
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.